MEDINET Co., Ltd. (JP:2370)
:2370
Want to see JP:2370 full AI Analyst Report?
2370 Stock Chart & Stats
¥29.00
-¥1.00(-2.70%)
At close: 4:00 PM EST
¥29.00
-¥1.00(-2.70%)
Day’s Range― - ―
52-Week Range¥27.00 - ¥43.00
Previous CloseN/A
Volume258.10K
Average Volume (3M)1.57M
Market Cap
¥7.81B
Enterprise Value¥5.57B
Total Cash (Recent Filing)¥5.03B
Total Debt (Recent Filing)¥91.32M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.29
Shares Outstanding278,917,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetMEDINET's near-zero debt position materially reduces solvency risk and preserves financial flexibility. Over the next several months this gives management time to address operating losses, execute restructuring or raise capital on more favorable terms, extending runway versus leveraged peers.
Recent Revenue GrowthTop-line growth of ~11.8% in FY2025 shows demand traction for its clinical-support services. Sustained revenue increases help absorb fixed costs, support scale efficiencies, and provide a runway to improve margins if cost structure stabilizes over the next few quarters.
Niche Clinical Research ServicesMEDINET's focus on medical and clinical research support places it in a structural outsourcing market with steady, specialized demand. This niche positioning supports recurring engagements and revenue durability, assuming the company maintains service quality and client relationships.
Bears Say
Persistent Large LossesNet margin around -168% and recurring operating losses materially erode retained earnings and limit internal funding. Persistent unprofitability constrains reinvestment in the business and increases dependence on external financing, raising execution and dilution risk over the medium term.
Severe Free Cash Flow DeteriorationConsistent negative operating cash flow and a ~780% drop in FY2025 free cash flow indicate real cash burn, not just accounting losses. This reduces liquidity, shortens runway, and heightens near-term funding needs, limiting the company's ability to invest or weather downturns without new capital.
Declining Gross MarginsA steep fall in gross margin from ~37.2% to ~13.5% suggests structural pricing or cost pressures in core services. Lower gross margins reduce the leverage from revenue growth to operating profit, making margin recovery and path to sustainable profitability more difficult without cost or pricing remediation.
MEDINET Co., Ltd. News
2370 FAQ
What was MEDINET Co., Ltd.’s price range in the past 12 months?
MEDINET Co., Ltd. lowest stock price was ¥27.00 and its highest was ¥43.00 in the past 12 months.
What is MEDINET Co., Ltd.’s market cap?
MEDINET Co., Ltd.’s market cap is ¥7.81B.
When is MEDINET Co., Ltd.’s upcoming earnings report date?
MEDINET Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 82 days.
How were MEDINET Co., Ltd.’s earnings last quarter?
MEDINET Co., Ltd. released its earnings results on May 13, 2026. The company reported -¥0.78 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.78.
Is MEDINET Co., Ltd. overvalued?
According to Wall Street analysts MEDINET Co., Ltd.’s price is currently Overvalued.
Does MEDINET Co., Ltd. pay dividends?
MEDINET Co., Ltd. does not currently pay dividends.
What is MEDINET Co., Ltd.’s EPS estimate?
MEDINET Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDINET Co., Ltd. have?
MEDINET Co., Ltd. has 278,917,330 shares outstanding.
What happened to MEDINET Co., Ltd.’s price movement after its last earnings report?
MEDINET Co., Ltd. reported an EPS of -¥0.78 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MEDINET Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2370
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MEDINET Co., Ltd.
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.
Technical Analysis
Linical Co., Ltd.
―
Trans Genic Inc.
―
Soiken Holdings Inc.
―
Takara Bio Inc.
―
PRISM BioLab Co. LTD
―